Friday, February 23, 2024
wellness India Expo
Home Tags Biocon

Tag: Biocon

Biocon included in S&P Global Sustainability Yearbook 2024

S&P Global ESG Score at 63; Inducted in Dow Jones Sustainability Emerging Markets Index for 3rd Year in a Row

Biocon Biologics partners Sandoz Australia for sale of biosimilars, Trastuzumab &...

The agreement is effective from January 1, 2024 and commercialization commenced on February 1, 2024

Biocon clocks Rs 4,519 crore revenue in Q3 of FY24, earns...

The company revenue in biosimilars went up by 65%; research services up by 9%; EBITDA stood at Rs 1,492 Crore, up 106%; Net Profit at Rs 660 Crore

Biocon Biologics appoints Sandoz as distributor for Adalimumab BS Subcutaneous Injection...

Adalimumab BS for subcutaneous injection [FKB] is a biosimilar of Humira® (generic name: adalimumab (genetical recombination)) and is indicated for immune-related diseases

Biocon Biologics concludes integration of acquired biosimilars business in 120 countries

Over 10 Emerging Markets along with Japan, Australia and New Zealand have transitioned in this final phase of the integration of the biosimilars business acquired from Viatris. 

Biocon Biologics successfully completes integration of Viatris’ biosimilar business in 31...

In Europe, Biocon Biologics portfolio includes 7 biosimilars: Insulin Aspart and Insulin Glargine, Bevacizumab, Pegfilgrastim, Trastuzumab, Adalimumab, and Etanercept

Biocon Biologics receives MHRA, UK approval for YESAFILI, a biosimilar of...

In September, YESAFILI®, received marketing authorization approval from the European Commission (EC) for the European Union (EU)

Biocon Biologics announces divestment of two non-core branded formulations business units

The move is in line with the company’s strategy to sharpen focus on core therapy areas as a fully integrated biosimilars company

Kedar Upadhye appointed as new CFO of Biocon Biologics

Current CFO MB Chinappa to take on a Strategic Finance role at Biocon Group

Biocon Biologics receives European Commission approval for YESAFILI biosimilar Aflibercept

Aflibercept had EU brand sales of approximately $1.8B for the 12 months ending December 31, 2022, according to IQVIA